Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TIR domain-containing adapter molecule 1 (TICAM1, also known as TRIF) is a cytoplasmic adaptor protein containing a Toll/interleukin-1 receptor (TIR) domain, essential for MyD88-independent signal transduction downstream of Toll-like receptors, primarily TLR3 and in part TLR4[1][2][3][5]. Upon TLR engagement by pathogen-associated molecular patterns, TICAM1 orchestrates the formation of signaling complexes ("speckles") in which it recruits effectors such as TRAF6 and TBK1, leading to phosphorylation and activation of IRF3 and NF-κB—key drivers of type I interferon and antiviral cytokine production[1][3][5]. TICAM1 plays a central role in the innate immune response to viral infection; defects or cleavage by viruses undermine host immunity[1]. Structurally, TICAM1 oligomerizes via its TIR domain, undergoing both homotypic and heterotypic interactions (especially with TICAM2), and its activity is essential for the formation of higher-order signalosomes crucial for propagating immune signals[5][7]. Defects or targeted inhibition of TICAM1 disrupt downstream pathway activation and raise susceptibility to infectious diseases[1][3][5].
- Inhibition of TICAM1 may suppress type I interferon response, blunting the antiviral defense[1]. - Modulation of its adaptor function (blocking or enhancing its ability to oligomerize or interact with TRAF6, TBK1, etc.) regulates downstream immune responses[2][5].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TIR domain-containing adapter molecule 1 (TICAM1 (also known as TRIF)).